# Non-Myeloablative Conditioning and Bone Marrow Transplantation

> **NCT01850108** · NA · UNKNOWN · sponsor: **Vanderbilt-Ingram Cancer Center** · enrollment: 26 (actual)

## Conditions studied

- Sickle Cell Disease
- Hemoglobinopathies

## Interventions

- **DRUG:** Thymoglobulin
- **DRUG:** Fludarabine
- **DRUG:** Cyclophosphamide (CTX)
- **DRUG:** Mesna
- **DRUG:** Sirolimus
- **DRUG:** Mycophenolate mofetil (MMF)
- **PROCEDURE:** Bone marrow transplantation
- **RADIATION:** Total body irradiation

## Key facts

- **NCT ID:** NCT01850108
- **Lead sponsor:** Vanderbilt-Ingram Cancer Center
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2013-05
- **Primary completion:** 2023-11
- **Final completion:** 2024-12-31
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2024-01-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01850108

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01850108, "Non-Myeloablative Conditioning and Bone Marrow Transplantation". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01850108. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*